Back to top
more

ProShares S&P 500 Dividend Aristocrats ETF: (NOBL)

(Delayed Data from NYSE MKT (ex. AMEX)) As of Feb 27, 2026 04:00 PM ET

$114.49 USD

114.4873
601,633

+0.65 (0.57%)

Volume: 601,633

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

3 - Hold of 5     3    

After-Market: $114.59 +0.10 (0.09 %) 7:58 PM ET

Zacks News

Zacks Equity Research

Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?

Smart Beta ETF report for NOBL

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Novo Nordisk, MakeMyTrip, Fastenal in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Santanu Roy  headshot

Beat the Market the Zacks Way: UnitedHealth, Novo Nordisk, Check Point Software in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Shopify, Caterpillar, Amgen in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Elementis, Novo Nordisk, Amgen in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Automatic Data Processing, Casey's, Paysafe in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Shopify, Novo Nordisk, Amgen in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: NVIDIA, Novo Nordisk, Matson in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Sanghamitra Saha headshot

Time for 60/40 Portfolio? ETFs in Focus

The 60/40 has proven to be one of the winning and time-tested strategies.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Hubbell, Adobe, Nikola in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.